Midnight Manhattan is a hybrid cannabis cultivar distributed within the regulated United States marketplace, primarily documented across Arizona dispensaries under brand labels such as Fleur and OZ Cannabis. Characterized as a balanced hybrid, the cultivar is noted for its high-tetrahydrocannabinol (THC) cannabinoid profile and monoterpene-rich profile led by myrcene. Because commercial propagators and distribution networks list its parental background as proprietary or undisclosed, the strain exists primarily as an operator-specific market offering rather than an open-source seedline.
Strain Profile & Genetics
- Type: Hybrid
- THC: Disputed (batch-tested from 16.86% to 28.3% across commercial lots)
- CBD: Tested as negligible / not detected
- Terpenes: Myrcene (dominant)
- Mental effects: Reported calm and euphoric mood elevation
- Body effects: Reported physical relaxation
Terpene Profile
Analytical lab testing from commercial Arizona batches shows a terpene matrix led predominantly by the monoterpene beta-myrcene. In published retail lab profiles, myrcene has registered at approximately 0.53% by weight, forming the backbone of the cultivar’s volatile aromatic spectrum. Total terpene concentrations vary depending on cultivation run and packaging format, with lab certificates reporting total terpene sums ranging between 1.33% and 2.02%.
Potency & Cannabinoids
Midnight Manhattan expresses a Chemotype I cannabinoid profile defined by high levels of delta-9-tetrahydrocannabinolic acid (THCA) and negligible amounts of cannabidiol (CBD). Quantitative testing across commercial production runs demonstrates significant variation across batches, packaging weights, and producer lines:
- Fleur 14g Whole Flower: Tested at 16.86% THC.
- JARS Kingman Preground: Tested at 21.74% THC.
- Fleur 3.5g Flower: Tested at 24.12% THC and 28.03% total active cannabinoids (TAC).
- OZ Cannabis 14g Pre-Roll Lots: Tested at 24.06% THC and 28.03% TAC.
- OZ Cannabis 3.5g Flower: Tested at 24.87% THC.
- OZ Cannabis 1g Pre-Roll: Tested at 25.83% THC and 30.09% TAC.
- Fleur 2.5g Dogwalker Pre-Roll: Tested at 28.3% THC.
Effects
Subjective experiences documented on dispensary menus and community consumer reports characterize Midnight Manhattan as providing a classic hybrid balance. Consumers reported mild physical relaxation accompanied by feelings of calm, happiness, and subtle mental stimulation. These reported effects are subjective and vary depending on individual endocannabinoid system responses, dosage, and specific batch terpene compositions.
Scientific & Botanical Overview
Botanically, Midnight Manhattan is classified as an indoor-cultivated Cannabis sativa L. hybrid cultivar exhibiting a Chemotype I phytochemical configuration. In analytical chemistry tests, the predominance of myrcene alongside significant THCA synthesis points to standard commercial polyhybrid heritage common to contemporary North American breeding pools. Without peer-reviewed microsatellite marker analysis or published genomic sequencing, the cultivar’s phylogenetic relationship to other modern cultivars remains speculative.
Lineage & Related Strains
Commercial packaging and retailer inventories consistently designate Midnight Manhattan’s genetic parentage as unknown or proprietary. The cultivar should not be conflated with the classic culinary cocktail of the same name, nor should it be confused with Tikun Olam’s proprietary cultivar “Midnight,” which is a 1:1 THC:CBD medicinal variety developed in Israel.
Sources & Data Notes
All strain-specific analytical values are compiled from licensed Arizona commercial testing certificates, product listings from JARS Cannabis dispensaries, and regional product databases for the Fleur and OZ Cannabis brands. Breeder catalogs and seed banks do not currently list Midnight Manhattan, reflecting its status as a licensed dispensary-exclusive cut.
Midnight Manhattan Summary
Midnight Manhattan is an Arizona-market hybrid cannabis cultivar characterized by a Chemotype I cannabinoid makeup (commercial batches ranging from 16.86% to 28.3% THC) and a myrcene-dominant terpene distribution totaling between 1.33% and 2.02%. Its parental lineage remains unverified in commercial registries.
